Miklos Pless
Papers
2
Total Citations
60
H-Index
2
About
Miklos Pless is a leading oncologist whose research focuses on urothelial carcinoma and genitourinary malignancies, with a particular emphasis on integrating immunotherapy into perioperative treatment paradigms. His major contributions include pioneering the use of chemoimmunotherapy combinations for muscle-invasive bladder cancer, as demonstrated in the SAKK 06/17 phase II trial, which explored durvalumab with cisplatin/gemcitabine before surgery. This work addresses the critical need to reduce relapse rates beyond standard neoadjuvant chemotherapy. Additionally, Dr. Pless has advanced the understanding of rare bladder tumors, notably characterizing an inflammatory myofibroblastic tumor with an FN1-ALK gene fusion and documenting its differential response to ALK inhibition with crizotinib. His most cited papers have garnered over 60 citations, reflecting their clinical relevance. Dr. Pless is also recognized for his leadership in Swiss cancer research and his commitment to translating molecular insights into targeted therapies, making him a key figure in improving outcomes for patients with challenging urologic cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2